VRTX · Full Picture

VERTEX PHARMACEUTICALS INC / MA — the full picture

Earnings window · 2026-07-14 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 90
   -43.3% cash; 3 sources (news, press_release, sec_filing); 8 forward row(s); quote_verified
   Vertex announced a planned acquisition of Crinetics Pharmaceuticals for approximately $10.0 billion to further expand its therapeutic portfolio.
2. Revenue Performance and Mix · Revenue growth & mixPriority 83
   +45.5% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verified
   Analysts forecast Vertex Pharmaceuticals will announce Q2 2026 earnings after market close on Monday, August 3, 2026, with expected EPS of $4.74 and revenue of $3.2285 billion.
3. Crinetics Acquisition Financing · M&A and divestituresPriority 80
   +18.2% assets; 2 sources (news, sec_filing); 4 forward row(s); quote_verified
   VERTEX PHARMACEUTICALS INC / MA acquired Crinetics Pharmaceuticals for an equity value of approximately $10.0 billion.
4. Product Launch and Transition · Products & launchesPriority 78
   +12.5% revenue (realized); 3 sources (news, press_release, sec_filing); 4 forward row(s); quote_verified
   ALYFTREK revenues for the three months ended June 30, 2026 were $573.6 million compared to $156.8 million in the prior year period.
5. Guidance and Outlook · Guidance & outlookPriority 76
   +5.1% revenue; 2 sources (news, press_release); 4 forward row(s); quote_verified
   Vertex Pharmaceuticals raised its 2026 revenue guidance to US$13.10–US$13.20 billion.
6. Operating Expense Trends · Operating expenses (SG&A)Priority 74
   -17.2% operating_income; 2 sources (press_release, sec_filing); 3 forward row(s); quote_verified
   Vertex reiterated full year 2026 guidance for combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses of $6.3 billion to $6.45 billion and $5.65 billion to $5.75 billion, respectively.
7. End-Market Demand Trends · Demand, orders & backlogPriority 63
   2 sources (news, sec_filing); 1 forward row(s); quote_verified
   Approximately 5,500 patients with SCD or TDT may be eligible for treatment with CASGEVY for the first time with this approval
8. Geographic Market Commentary · Geographic mixPriority 55
   +6.1% revenue (realized); 2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
   Vertex signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance for reimbursement of ALYFTREK for eligible patients 6 years and older in Canada.
9. Liquidity and Debt Position · Debt, leverage & refinancingPriority 54
   -0.6% liability; 2 forward row(s); quote_verified
   Company expects cash, cash equivalents and current marketable securities together with operating profitability will be sufficient to fund operations for at least the next twelve months
10. Capital Return Program · Buybacks & dividendsPriority 52
    -5.2% cash (realized); 2 sources (news, sec_filing); quote_verified
    As of June 30, 2026, $2.6 billion remaining available under the share repurchase program authorized in May 2025; program has no expiration date
11. Income Tax Rate Changes · TaxPriority 49
    2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
    U.S. enacted H.R.1 in July 2025 including provisions to immediately deduct R&D expenditures for 2025; H.R.1 does not have a material impact on U.S. taxes for first half of 2026 but may impact future effective tax rates
12. Gross Margin Drivers · Gross marginPriority 47
    -3.3% operating_income (realized); 2 sources (press_release, sec_filing); structured_verified
    Cost of sales in Q2 2026: $489.2 million, up 20% from $407.5 million in Q2 2025; cost of sales for six months ended June 30, 2026: $882.0 million, up 14% from $770.5 million

Threads by pillar

Revenue & Demand Priority 93 · 7 threads

• Revenue Performance and MixPriority 83 · News, Release, Filing
• Product Launch and TransitionPriority 78 · News, Release, Filing
• Product / Drug Pipeline ProgressPriority 44 · News, Release
• End-Market Demand TrendsPriority 63 · News, Filing
• JOURNAVX Demand and AccessPriority 42 · News, Release
• Geographic Market CommentaryPriority 55 · Release, Filing
• Geographic Revenue ShiftPriority 42 · Filing

Costs & Margins Priority 81 · 4 threads

• Operating Expense TrendsPriority 74 · Release, Filing
• Gross Margin DriversPriority 47 · Release, Filing
• Operating Income and MarginsPriority 40 · Release
• Supply Chain ConstraintsPriority 23 · Filing

Capital & Balance Sheet Priority 69 · 3 threads

• Liquidity and Debt PositionPriority 54 · Filing
• Capital Return ProgramPriority 52 · News, Filing
• Income Tax Rate ChangesPriority 49 · Release, Filing

Strategy & Portfolio Priority 94 · 4 threads

• Acquisition / Partnership / DivestiturePriority 90 · News, Release, Filing
• Crinetics Acquisition FinancingPriority 80 · News, Filing
• CASGEVY Pediatric Market ExpansionPriority 43 · News, Release
• Licensing / Collaboration DealsPriority 27 · News

Legal, Regulatory & Policy Priority 56 · 3 threads

• Litigation and Legal RiskPriority 42 · News, Filing
• Regulatory Approval MilestonesPriority 42 · News, Release, Filing
• Reimbursement and Payer MixPriority 30 · Filing

Guidance & Outlook Priority 76 · 1 thread

• Guidance and OutlookPriority 76 · News, Release

Macro & Market Conditions Priority 44 · 4 threads

• KALYDECO Generic CompetitionPriority 37 · News
• Competition and Market PositionPriority 23 · News
• IgAN Competition and DifferentiationPriority 22 · News
• FX / Currency ImpactPriority 30 · Release

Unclassified Priority 41 · 1 thread

• Liquidity and Debt PositionPriority 41 · Release

Expected impact by metric